X

Drug Profile

Research programme: central nervous system disorder therapies - Mabylon

Latest Information Update: 22 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mabylon
Class Antibodies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Amyotrophic lateral sclerosis; Frontotemporal dementia

Most Recent Events

22 Feb 2022 Preclinical trials in Amyotrophic lateral sclerosis in Switzerland (unspecified route) (Mabylon pipeline, February 2022)
22 Feb 2022 Preclinical trials in Frontotemporal dementia in Switzerland (unspecified route) (Mabylon pipeline, February 2022)
10 Feb 2022 Mabylon and SciNeuro Pharmaceuticals agree to co-develop therapeutics for neurological diseases and licensed to later in Greater China for commercialization

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com